Success Metrics

Clinical Success Rate
69.5%

Based on 41 completed trials

Completion Rate
69%(41/59)
Active Trials
0(0%)
Results Posted
76%(31 trials)
Terminated
18(26%)

Phase Distribution

Ph phase_4
20
29%
Ph early_phase_1
1
1%
Ph not_applicable
5
7%
Ph phase_1
9
13%
Ph phase_3
15
22%
Ph phase_2
15
22%

Phase Distribution

10

Early Stage

15

Mid Stage

35

Late Stage

Phase Distribution65 total trials
Early Phase 1First-in-human
1(1.5%)
Phase 1Safety & dosage
9(13.8%)
Phase 2Efficacy & side effects
15(23.1%)
Phase 3Large-scale testing
15(23.1%)
Phase 4Post-market surveillance
20(30.8%)
N/ANon-phased studies
5(7.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

67.2%

41 of 61 finished

Non-Completion Rate

32.8%

20 ended early

Currently Active

0

trials recruiting

Total Trials

69

all time

Status Distribution
Completed(41)
Terminated(20)
Other(8)

Detailed Status

Completed41
Terminated18
unknown8
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
69
Active
0
Success Rate
69.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.5%)
Phase 19 (13.8%)
Phase 215 (23.1%)
Phase 315 (23.1%)
Phase 420 (30.8%)
N/A5 (7.7%)

Trials by Status

unknown812%
withdrawn23%
completed4159%
terminated1826%

Recent Activity

0 active trials
Showing 5 of 69
completedphase_1

Subcutaneous Daptomycin in Healthy Volunteers (DAPTOSC)

NCT04434300
completedphase_2

DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

NCT04775953
completedphase_2

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

NCT04983901
completedphase_2

Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis

NCT03480191
terminatedphase_3

Application of Daptomycin in MRSA Infected Diabetic Foot in Comparison to Vancomycin Treatment

NCT01199783
View all 69 trials

Clinical Trials (69)

Showing 20 of 69 trialsScroll for more
NCT04434300Phase 1

Subcutaneous Daptomycin in Healthy Volunteers (DAPTOSC)

Completed
NCT04775953Phase 2

DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

Completed
NCT04983901Phase 2

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

Completed
NCT03480191Phase 2

Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis

Completed
NCT01199783Phase 3

Application of Daptomycin in MRSA Infected Diabetic Foot in Comparison to Vancomycin Treatment

Terminated
NCT03138733Phase 3

Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

Completed
NCT01734694Phase 4

Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients

Terminated
NCT04132115

Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)

Unknown
NCT00467272Phase 2

Catheter Related - Gram Positive Bloodstream Infections

Completed
NCT00638157Phase 4

Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)

Terminated
NCT04277143

A Pharmacokinetics Study of Daptomycin in Critically Ill Patients and Effects of Daptomycin on Kidney

Unknown
NCT02972983Phase 4

Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia

Completed
NCT04546815

The Efficacy and Safety of Daptomycin in the Treatment of Gram-positive Bacterial Infection.

Unknown
NCT01792804Phase 3

Staphylococcus Aureus Bacteremia Antibiotic Treatment Options

Completed
NCT00136292Phase 1

Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics

Completed
NCT02208063Phase 3

A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

Terminated
NCT00540072Phase 3

Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae

Completed
NCT00538694Phase 3

Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia

Completed
NCT00679835Phase 1

PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive Infections

Completed
NCT01019395Phase 1

Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics

Completed

Drug Details

Intervention Type
DRUG
Total Trials
69